Prekyba FibroGen, Inc - FGEN CFD
Pridėti prie mėgstamų- Santrauka
- Istoriniai duomenys
- Įvykiai
- Pajamų ataskaita
- Balansas
- Pinigų srautai
- Nuosavybė
Prekybos sąlygos
| Skirtumas | 0.17 | ||||||||
|
Ilgos pozicijos nakties mokestis
Long position overnight fee
Eiti į platformą | -0.025457% | ||||||||
|
Trumpos pozicijos nakties mokestis
Short position overnight fee
Eiti į platformą | 0.003235% | ||||||||
| Nakties mokesčio laikas | 21:00 (UTC) | ||||||||
| Mažiausias parduodamas kiekis | 1 | ||||||||
| Valiuta | USD | ||||||||
| Marža | 20% | ||||||||
| Akcijų birža | United States of America | ||||||||
| Prekybos mokesčiai | 0% |
*Information provided by Capital.com
FibroGen Inc ESG Risk Ratings
High Medium Low Negligible
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Pagrindiniai statistiniai duomenys
| Ankstesnis uždarymas* | 16.82 |
| Atviras* | 16.65 |
| 1 metų pokytis* | 93.38% |
| Dienos intervalas* | 16.33 - 16.76 |
| 52 savaičių intervalas | 8.67-25.69 |
| Vidutinė apimtis (10 dienų) | 784.84K |
| Vidutinė apimtis (3 mėn.) | 19.37M |
| Rinkos kapitalizacija | 1.63B |
| P/E santykis | -100.00K |
| Neišpirktos akcijos | 97.58M |
| Pajamos | 116.07M |
| EPS | -3.27 |
| Dividendai (pajamingumas %) | N/A |
| Beta | 0.78 |
| Kito pelno data | Aug 7, 2023 |
Visus duomenis pateikė Refinitiv, išskyrus žvaigždute pažymėtus duomenis, kurie yra Capital.com pateikti *duomenys
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Uždarymas | Change | Change (%) | Atidarymas | High | Low |
|---|---|---|---|---|---|---|
| May 26, 2023 | 16.65 | 0.03 | 0.18% | 16.62 | 16.80 | 16.33 |
| May 25, 2023 | 16.82 | 0.16 | 0.96% | 16.66 | 16.91 | 16.44 |
| May 24, 2023 | 16.90 | -0.05 | -0.29% | 16.95 | 17.33 | 16.51 |
| May 23, 2023 | 17.27 | 0.06 | 0.35% | 17.21 | 18.03 | 16.99 |
| May 22, 2023 | 17.16 | -0.14 | -0.81% | 17.30 | 18.02 | 16.96 |
| May 19, 2023 | 17.49 | -0.07 | -0.40% | 17.56 | 18.07 | 17.20 |
| May 18, 2023 | 17.53 | 0.01 | 0.06% | 17.52 | 17.89 | 17.29 |
| May 17, 2023 | 17.77 | 0.80 | 4.71% | 16.97 | 17.86 | 16.92 |
| May 16, 2023 | 17.40 | 0.25 | 1.46% | 17.15 | 17.51 | 17.08 |
| May 15, 2023 | 17.58 | 0.46 | 2.69% | 17.12 | 17.91 | 17.03 |
| May 12, 2023 | 17.31 | -0.11 | -0.63% | 17.42 | 17.66 | 17.09 |
| May 11, 2023 | 17.48 | -0.12 | -0.68% | 17.60 | 18.00 | 17.38 |
| May 10, 2023 | 17.65 | 0.25 | 1.44% | 17.40 | 17.84 | 17.17 |
| May 9, 2023 | 17.30 | 1.25 | 7.79% | 16.05 | 17.89 | 15.97 |
| May 8, 2023 | 17.61 | 0.58 | 3.41% | 17.03 | 17.73 | 16.55 |
| May 5, 2023 | 17.29 | 1.14 | 7.06% | 16.15 | 17.55 | 15.83 |
| May 4, 2023 | 16.68 | 0.36 | 2.21% | 16.32 | 16.85 | 15.93 |
| May 3, 2023 | 16.52 | 0.48 | 2.99% | 16.04 | 17.04 | 15.95 |
| May 2, 2023 | 16.06 | -0.12 | -0.74% | 16.18 | 16.55 | 15.93 |
| May 1, 2023 | 16.39 | -0.42 | -2.50% | 16.81 | 17.20 | 16.17 |
FibroGen, Inc Events
| Laikas (UTC) (UTC) | Šalis | Įvykis |
|---|---|---|
| Wednesday, June 7, 2023 | ||
| Laikas (UTC) (UTC) 15:00 | Šalis US
| Įvykis FibroGen Inc Annual Shareholders Meeting FibroGen Inc Annual Shareholders MeetingForecast -Previous - |
| Friday, June 16, 2023 | ||
| Laikas (UTC) (UTC) 15:00 | Šalis US
| Įvykis FibroGen Inc Annual Shareholders Meeting FibroGen Inc Annual Shareholders MeetingForecast -Previous - |
| Monday, August 7, 2023 | ||
| Laikas (UTC) (UTC) 10:59 | Šalis US
| Įvykis Q2 2023 FibroGen Inc Earnings Release Q2 2023 FibroGen Inc Earnings ReleaseForecast -Previous - |
| Monday, November 6, 2023 | ||
| Laikas (UTC) (UTC) 10:59 | Šalis US
| Įvykis Q3 2023 FibroGen Inc Earnings Release Q3 2023 FibroGen Inc Earnings ReleaseForecast -Previous - |
- Metinis
- Kas ketvirtį
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Visos pajamos | 140.734 | 235.309 | 176.319 | 256.577 | 212.958 |
| Pajamos | 140.734 | 235.309 | 176.319 | 256.577 | 212.958 |
| Pajamų sąnaudos, iš viso | 441.759 | 523.839 | 368.199 | 345.891 | 299.651 |
| Pardavimas / Bendrosios / administravimo išlaidos, iš viso | 127.474 | 120.557 | 97.238 | 126.557 | 63.812 |
| Tyrimai ir plėtra | 296.791 | 387.043 | 252.924 | 209.265 | 235.839 |
| Veiklos pajamos | -301.025 | -288.53 | -191.88 | -89.314 | -86.693 |
| Palūkanų pajamos (išlaidos), grynosios ne veiklos pajamos | 6.156 | -2.153 | 3.151 | 12.672 | 0.577 |
| Grynosios pajamos prieš mokesčius | -294.869 | -290.683 | -188.729 | -76.642 | -86.116 |
| Grynosios pajamos po mokesčių | -295.227 | -291.03 | -189.089 | -76.97 | -86.42 |
| Grynosios pajamos prieš papildomas. Prekės | -293.654 | -290.023 | -189.291 | -76.97 | -86.42 |
| Grynosios pajamos | -293.654 | -290.023 | -189.291 | -76.97 | -86.42 |
| Pajamos, kurias galima gauti bendrai, išskyrus papildomas pajamas. Prekės | -293.654 | -290.023 | -189.291 | -76.97 | -86.42 |
| Pajamos, kurias galima gauti bendrai, įskaitant papildomas pajamas. Prekės | -293.654 | -290.023 | -189.291 | -76.97 | -86.42 |
| Skiedžiamas grynasis pelnas | -293.654 | -290.023 | -189.291 | -76.97 | -86.42 |
| Skiedžiamas svertinis vidutinis akcijų skaičius | 93.582 | 92.349 | 89.854 | 86.633 | 84.062 |
| Skiedžiamas pelnas už akcijas, neįskaitant ypatingų prekių | -3.13793 | -3.14051 | -2.10665 | -0.88846 | -1.02805 |
| Skiedžiamas normalizuotas pelnas, gautas iš pelno | -3.13793 | -3.14051 | -2.10665 | -0.88846 | -1.02805 |
| Iš viso nepaprastųjų prekių | |||||
| Bendros pajamos, iš viso | 20.28 | 12.871 | 8.869 | 1.147 | |
| Pajamos | 120.454 | 222.438 | 167.45 | 255.43 | |
| Depreciation / Amortization | 0.587 | 4.639 | 10.369 | 10.307 | |
| Other Operating Expenses, Total | -3.373 | -1.271 | -1.201 | -1.385 | |
| Equity In Affiliates | 1.573 | 1.007 | -0.202 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Visos pajamos | 36.161 | 34.367 | 15.735 | 29.806 | 60.827 |
| Pajamos | 36.161 | 34.367 | 15.735 | 29.806 | 60.827 |
| Bendros pajamos, iš viso | 3.491 | 4.925 | 4.308 | 6.809 | 4.238 |
| Pajamos | 32.67 | 29.442 | 11.427 | 22.997 | 56.589 |
| Pajamų sąnaudos, iš viso | 112.252 | 100.519 | 109.392 | 108.03 | 123.82 |
| Pardavimas / Bendrosios / administravimo išlaidos, iš viso | 34.275 | 33.966 | 29.902 | 30.258 | 30.564 |
| Tyrimai ir plėtra | 74.486 | 61.628 | 75.182 | 70.963 | 89.018 |
| Other Operating Expenses, Total | |||||
| Veiklos pajamos | -76.091 | -66.152 | -93.657 | -78.224 | -62.993 |
| Palūkanų pajamos (išlaidos), grynosios ne veiklos pajamos | -1.336 | -0.195 | 1.714 | 5.058 | -0.419 |
| Grynosios pajamos prieš mokesčius | -77.427 | -66.347 | -91.943 | -73.166 | -63.412 |
| Grynosios pajamos po mokesčių | -77.501 | -66.455 | -92.057 | -73.189 | -63.525 |
| Equity In Affiliates | 0.796 | 0.28 | 0.407 | 0.565 | 0.32 |
| Grynosios pajamos prieš papildomas. Prekės | -76.705 | -66.175 | -91.65 | -72.624 | -63.205 |
| Grynosios pajamos | -76.705 | -66.175 | -91.65 | -72.624 | -63.205 |
| Pajamos, kurias galima gauti bendrai, išskyrus papildomas pajamas. Prekės | -76.705 | -66.175 | -91.65 | -72.624 | -63.205 |
| Pajamos, kurias galima gauti bendrai, įskaitant papildomas pajamas. Prekės | -76.705 | -66.175 | -91.65 | -72.624 | -63.205 |
| Skiedžiamas grynasis pelnas | -76.705 | -66.175 | -91.65 | -72.624 | -63.205 |
| Skiedžiamas svertinis vidutinis akcijų skaičius | 94.691 | 94.035 | 93.767 | 93.475 | 93.043 |
| Skiedžiamas pelnas už akcijas, neįskaitant ypatingų prekių | -0.81006 | -0.70373 | -0.97742 | -0.77694 | -0.67931 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Skiedžiamas normalizuotas pelnas, gautas iš pelno | -0.81006 | -0.70373 | -0.97742 | -0.77694 | -0.67931 |
- Metinis
- Kas ketvirtį
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Trumpalaikis turtas iš viso | 492.826 | 474.059 | 755.11 | 702.49 | 690.015 |
| Pinigai ir trumpalaikės investicijos | 422.008 | 405.19 | 686.537 | 533.757 | 621.402 |
| Cash | 135.819 | 111.422 | 88.046 | 40.715 | 38.783 |
| Pinigai ir ekvivalentai | 19.881 | 59.801 | 590.347 | 85.551 | 50.475 |
| Trumpalaikės investicijos | 266.308 | 233.967 | 8.144 | 407.491 | 532.144 |
| Gautinos sumos, iš viso, grynąja verte | 16.299 | 25.401 | 41.883 | 153.665 | 63.684 |
| Accounts Receivable - Trade, Net | 28.387 | 36.331 | 46.01 | 158.51 | 16.474 |
| Prepaid Expenses | 9.73 | 7.383 | 8.353 | 6.464 | 4.929 |
| Total Assets | 610.087 | 773.821 | 826.84 | 857.397 | 880.598 |
| Property/Plant/Equipment, Total - Net | 100.933 | 120.15 | 65.296 | 84.276 | 127.198 |
| Property/Plant/Equipment, Total - Gross | 253.644 | 252.362 | 199.305 | 195.752 | 192.397 |
| Accumulated Depreciation, Total | -152.711 | -132.212 | -134.009 | -111.476 | -65.199 |
| Long Term Investments | 9.409 | 171.621 | 2.972 | 61.118 | 55.82 |
| Other Long Term Assets, Total | 6.919 | 7.991 | 3.462 | 9.513 | 7.565 |
| Total Current Liabilities | 273.562 | 225.497 | 163.187 | 102.745 | 89.033 |
| Accounts Payable | 30.758 | 26.097 | 24.789 | 6.088 | 9.139 |
| Accrued Expenses | 229.639 | 180.356 | 104.384 | 83.816 | 66.123 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 13.129 | 19.033 | 21.684 | 0.49 | 13.771 |
| Total Liabilities | 631.534 | 564.675 | 404.662 | 341.262 | 371.399 |
| Total Long Term Debt | 17.054 | 17.616 | 44.088 | 55.531 | 113.955 |
| Long Term Debt | 16.917 | 17.613 | 18.697 | 16.78 | 16.798 |
| Capital Lease Obligations | 0.137 | 0.003 | 25.391 | 38.751 | 97.157 |
| Minority Interest | 19.967 | 19.967 | 19.271 | 19.271 | 19.271 |
| Other Liabilities, Total | 320.951 | 292.403 | 169.441 | 163.715 | 149.14 |
| Total Equity | -21.447 | 209.146 | 422.178 | 516.135 | 509.199 |
| Redeemable Preferred Stock | 0 | 0 | 0 | 0 | 0 |
| Common Stock | 0.942 | 0.929 | 0.914 | 0.877 | 0.854 |
| Additional Paid-In Capital | 1541.02 | 1476.41 | 1399.77 | 1300.72 | 1226.45 |
| Retained Earnings (Accumulated Deficit) | -1557.69 | -1264.03 | -974.011 | -784.72 | -715.827 |
| Other Equity, Total | -5.72 | -4.163 | -4.499 | -0.747 | -2.281 |
| Total Liabilities & Shareholders’ Equity | 610.087 | 773.821 | 826.84 | 857.397 | 880.598 |
| Total Common Shares Outstanding | 94.1661 | 92.881 | 91.441 | 87.657 | 85.432 |
| Total Inventory | 40.436 | 31.015 | 16.53 | 6.887 | |
| Other Current Assets, Total | 4.353 | 5.07 | 1.807 | 1.717 | |
| Current Port. of LT Debt/Capital Leases | 0.036 | 0.011 | 12.33 | 12.351 | |
| Deferred Income Tax | 9.192 | 8.675 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Trumpalaikis turtas iš viso | 430.549 | 492.826 | 474.224 | 520.643 | 524.415 |
| Pinigai ir trumpalaikės investicijos | 355.949 | 422.008 | 408.52 | 438.133 | 428.075 |
| Cash | 145.81 | 135.819 | 104.509 | 128.152 | 165.436 |
| Pinigai ir ekvivalentai | 42.74 | 19.881 | 51.451 | 39.606 | 20.46 |
| Trumpalaikės investicijos | 167.399 | 266.308 | 252.56 | 270.375 | 242.179 |
| Gautinos sumos, iš viso, grynąja verte | 17.654 | 16.299 | 15.328 | 33.573 | 43.883 |
| Accounts Receivable - Trade, Net | 29.217 | 28.387 | 29.665 | 60.352 | 82.638 |
| Total Inventory | 42.456 | 40.436 | 39.95 | 40.899 | 43.067 |
| Prepaid Expenses | 14.49 | 9.73 | 10.426 | 8.038 | 9.39 |
| Other Current Assets, Total | 4.353 | ||||
| Total Assets | 538.544 | 610.087 | 608.837 | 686.789 | 745.934 |
| Property/Plant/Equipment, Total - Net | 95.367 | 100.933 | 105.19 | 109.159 | 114.871 |
| Property/Plant/Equipment, Total - Gross | 253.644 | ||||
| Accumulated Depreciation, Total | -152.711 | ||||
| Long Term Investments | 5.884 | 9.409 | 22.411 | 50.414 | 97.643 |
| Other Long Term Assets, Total | 6.744 | 6.919 | 7.012 | 6.573 | 9.005 |
| Total Current Liabilities | 254.746 | 273.562 | 251.994 | 240.34 | 255.374 |
| Accounts Payable | 71.282 | 30.758 | 19.323 | 29.36 | 36.353 |
| Accrued Expenses | 166.969 | 229.639 | 224.577 | 202.681 | 211.518 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 0.036 | ||||
| Other Current Liabilities, Total | 16.495 | 13.129 | 8.094 | 8.299 | 7.503 |
| Total Liabilities | 587.396 | 631.534 | 582.531 | 583.009 | 587.886 |
| Total Long Term Debt | 17.276 | 17.054 | 15.422 | 16.439 | 17.374 |
| Long Term Debt | 17.276 | 16.917 | 15.422 | 16.439 | 17.374 |
| Capital Lease Obligations | 0.137 | ||||
| Deferred Income Tax | |||||
| Minority Interest | 19.967 | 19.967 | 19.967 | 19.967 | 19.967 |
| Other Liabilities, Total | 295.407 | 320.951 | 295.148 | 306.263 | 295.171 |
| Total Equity | -48.852 | -21.447 | 26.306 | 103.78 | 158.048 |
| Redeemable Preferred Stock | 0 | 0 | 0 | 0 | |
| Common Stock | 0.966 | 0.942 | 0.939 | 0.937 | 0.933 |
| Additional Paid-In Capital | 1589.15 | 1541.02 | 1524.23 | 1509.64 | 1490.86 |
| Retained Earnings (Accumulated Deficit) | -1634.39 | -1557.69 | -1491.51 | -1399.86 | -1327.24 |
| Other Equity, Total | -4.57 | -5.72 | -7.346 | -6.93 | -6.505 |
| Total Liabilities & Shareholders’ Equity | 538.544 | 610.087 | 608.837 | 686.789 | 745.934 |
| Total Common Shares Outstanding | 96.623 | 94.1661 | 93.936 | 93.733 | 93.289 |
- Metinis
- Kas ketvirtį
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Grynosios pajamos / pradinė eilutė | -293.654 | -290.023 | -189.291 | -76.97 | -86.42 |
| Pagrindinės veiklos pinigai | -145.933 | -82.232 | 81.602 | -78.705 | -76.144 |
| Pagrindinės veiklos pinigai | 10.604 | 14.809 | 22.047 | 21.454 | 6.562 |
| Nepiniginės prekės | 66.687 | 132.899 | 74.216 | 62.47 | 52.112 |
| Sumokėtos palūkanos grynaisiais pinigais | 0.104 | 0.094 | 0.135 | 0.174 | 0.218 |
| Apyvartinio kapitalo pokyčiai | 70.43 | 60.083 | 174.63 | -85.659 | -48.398 |
| Investicinės veiklos pinigai | 89.116 | -426.972 | 452.487 | 120.018 | -522.123 |
| Kapitalo išlaidos | -38.741 | -30.186 | -3.994 | -5.762 | -8.02 |
| Kiti investiciniai pinigų srautų iš prekių, iš viso | 127.857 | -396.786 | 456.481 | 125.78 | -514.103 |
| Finansinės veiklos pinigai | 46.776 | -0.563 | 13.343 | -4.3 | 13.875 |
| Finansavimo pinigų srautų prekės | -6.62 | -7.372 | -11.463 | -12.75 | -15.612 |
| Akcijų išleidimas (išpirkimas), grynasis | 53.934 | 12.701 | 37.829 | 20.778 | 29.847 |
| Skolos išleidimas (padengimas), grynasis | -0.538 | -5.892 | -13.023 | -12.328 | -0.36 |
| Užsienio valiutos keitimo įtaka | -5.482 | 2.597 | 4.695 | -0.005 | -0.008 |
| Grynasis pinigų pokytis | -15.523 | -507.17 | 552.127 | 37.008 | -584.4 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -76.705 | -293.654 | -227.479 | -135.829 | -63.205 |
| Cash From Operating Activities | -101.591 | -145.933 | -93.42 | -41.54 | -8.476 |
| Cash From Operating Activities | 2.965 | 10.604 | 7.914 | 5.235 | 2.584 |
| Non-Cash Items | 18.148 | 66.687 | 49.928 | 34.441 | 17.77 |
| Changes in Working Capital | -45.999 | 70.43 | 76.217 | 54.613 | 34.375 |
| Cash From Investing Activities | 103.482 | 89.116 | 88.023 | 43.24 | 25.935 |
| Capital Expenditures | -0.591 | -38.741 | -38.408 | -37.543 | -36.638 |
| Other Investing Cash Flow Items, Total | 104.073 | 127.857 | 126.431 | 80.783 | 62.573 |
| Cash From Financing Activities | 31.485 | 46.776 | -1.898 | -0.806 | -2.893 |
| Financing Cash Flow Items | 0 | -6.62 | -4.562 | -3.361 | -2.974 |
| Issuance (Retirement) of Stock, Net | 31.657 | 53.934 | 2.989 | 2.779 | 0.183 |
| Issuance (Retirement) of Debt, Net | -0.172 | -0.538 | -0.325 | -0.224 | -0.102 |
| Foreign Exchange Effects | -0.526 | -5.482 | -7.968 | -4.359 | 0.107 |
| Net Change in Cash | 32.85 | -15.523 | -15.263 | -3.465 | 14.673 |
| Investuotojo pavadinimas | Investuotojo tipas | Apyvartoje esantis procentas | Turimos akcijos | Turimų akcijų pokytis | Turėjimo data | Apyvartos vertinimas |
|---|---|---|---|---|---|---|
| PRIMECAP Management Company | Investment Advisor | 14.4767 | 14126697 | 231619 | 2023-03-31 | LOW |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 9.0286 | 8810326 | -613439 | 2023-03-31 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 6.2737 | 6122003 | 89685 | 2023-03-31 | LOW |
| Astellas Pharma Inc | Corporation | 5.0915 | 4968367 | 0 | 2023-01-31 | LOW |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 4.1772 | 4076167 | -188810 | 2023-03-31 | LOW |
| Point72 Asset Management, L.P. | Hedge Fund | 3.5113 | 3426427 | -1355218 | 2023-03-31 | LOW |
| First Trust Advisors L.P. | Investment Advisor | 2.7884 | 2720975 | -254678 | 2023-03-31 | LOW |
| Baker Bros. Advisors LP | Hedge Fund | 2.7027 | 2637384 | 1262173 | 2023-03-31 | LOW |
| Armistice Capital LLC | Hedge Fund | 2.3693 | 2312000 | -1552000 | 2023-03-31 | HIGH |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.7703 | 1727545 | 70450 | 2023-03-31 | LOW |
| Two Sigma Investments, LP | Hedge Fund | 1.7676 | 1724909 | 512435 | 2023-03-31 | HIGH |
| Schroder Investment Management North America Inc. | Investment Advisor | 1.5138 | 1477161 | -246616 | 2023-03-31 | LOW |
| Artisan Partners Limited Partnership | Investment Advisor | 1.3847 | 1351230 | 1351230 | 2023-03-31 | LOW |
| Assenagon Asset Management S.A. | Investment Advisor | 1.3779 | 1344583 | 1344583 | 2023-03-31 | HIGH |
| Jacobs Levy Equity Management, Inc. | Investment Advisor/Hedge Fund | 1.1877 | 1159027 | -348288 | 2023-03-31 | MED |
| Pictet Asset Management Ltd. | Investment Advisor/Hedge Fund | 1.1157 | 1088768 | 593915 | 2023-03-31 | LOW |
| Eventide Asset Management, LLC | Investment Advisor | 0.9838 | 960000 | 960000 | 2023-03-31 | MED |
| Nuveen LLC | Pension Fund | 0.9185 | 896293 | 328958 | 2023-03-31 | LOW |
| Adage Capital Management, L.P. | Hedge Fund | 0.8711 | 850000 | -1800000 | 2023-03-31 | LOW |
| Eagle Asset Management, Inc. | Investment Advisor/Hedge Fund | 0.8488 | 828307 | -74825 | 2023-03-31 | LOW |
Kodėl Capital.com? Mūsų skaičiai kalba už save.
Capital.com Group530K+
Prekeiviai
87K+
Aktyvūs klientai kas mėnesį
$46M+
Mėnesio investicijų apimtis
$31M+
Atsiimama kas mėnesį
Prekybos skaičiuoklė
Apskaičiuokite savo hipotetinį pelną ir pelną, jei CFD sandorį atidarėte tam tikrą dieną (pasirinkite datą) ir uždarėte kitą dieną (pasirinkite datą).
Sandorio komisiniai mokesčiai
0
- 1:1
Svertas
1:1
- 20
- 100
- 500
- 1000
- 10000
Investavimas
Sandorio dydis (finansinis svertas x investicija):
Atidarymas
Uždarymas
Trumpoji Ilgoji
FibroGen, Inc Company profile
Apie FibroGen, Inc
"FibroGen, Inc." yra biofarmacijos įmonė. Bendrovė atranda, kuria ir komercializuoja pirmos klasės gydymo priemones. Bendrovė taiko hipoksiją indukuojančio faktoriaus (HIF) biologijos, 2-oksoglutarato enzimologijos ir jungiamojo audinio augimo faktoriaus (CTGF) biologijos gebėjimus, kad sukurtų vaistus anemijai, fibrozinėms ligoms ir vėžiui gydyti. Bendrovės produktas "Roxadustat" yra geriamasis mažų molekulių HIF-prolilio hidroksilazės (HIF-PH) aktyvumo inhibitorius, skirtas lėtinės inkstų ligos sukeltai anemijai gydyti. Bendrovė taip pat kuria "Roxadustat" anemijai, susijusiai su mielodisplastiniais sindromais (MDS), gydyti. Bendrovė taip pat kuria "Roxadustat" chemoterapijos sukeltai anemijai (CIA) gydyti. Pamrevlumabas - žmogaus monokloninis antikūnas prieš CTGF, skirtas idiopatinei plaučių fibrozei (IPF), lokaliai pažengusiam neresekcionuojamam kasos vėžiui (LAPC) ir Diušeno raumenų distrofijai (DMD) gydyti.
| Industry: | Biotechnology & Medical Research (NEC) |
409 Illinois Street
SAN FRANCISCO
CALIFORNIA 94158
US
Pajamų ataskaita
- Annual
- Quarterly
Žmonės taip pat žiūri
Vis dar ieškote brokerio kuriuo galėtumėte pasitikėti?
Prisijunkite prie 530 000+ prekeivių visame pasaulyje, kurie pasirinko prekybą su Capital.com